(BFM Bourse) – Data on the immunogenicity and safety of this vaccine from a clinical trial confirmed the immune response enabled by this vaccine during a second booster dose.
Valneva continues to demonstrate the robustness of its vaccine portfolio. And to prove wrong those who saw the laboratory only as a “Covid value” on the stock market in 2020 and 2021. The group specializing in vaccines against infectious diseases published new encouraging data on Tuesday for its vaccine against Lyme disease.
Caused by tick bites, this disease can lead to joint, nerve or skin complications if not treated in the primary stage.
Valneva has developed a vaccine candidate, called VLA-15, to treat this disease, in partnership with the American giant Pfizer, which had also taken a 90 million euro stake in the French company in 2022. These funds were used to finance phase III studies, the last stage of clinical trials before the potential marketing of a treatment, which began in August 2022 and are still ongoing.
>> Access our exclusive graphic analyses, and enter the Trading Portfolio’s confidence
A confirmed profit
The data published by Valneva come from phase II, an intermediate stage which aims to demonstrate the efficacy of a treatment (while phase III evaluates its therapeutic interest and its benefit/cost ratio).
These data concerned the immunogenicity (the ability to elicit an immune response) and safety (the absence of risks) of the vaccine candidate.
These data showed that “the immune response and safety profile of VLA15 one month after receiving (a) second booster dose were similar to those reported after receiving the first booster dose, demonstrating the potential benefit that a booster vaccination could have before each Lyme disease season,” Valneva explained.
“We are encouraged by these data, which confirm the potential benefit of booster doses in all age groups evaluated,” said the company’s director of medical research, Juan Carlos Jaramillo, quoted in the statement.
On the Paris Stock Exchange, Valneva shares rose slightly following this news, gaining 4.2% shortly after 10am, the biggest increase on the SBF 120.
Back to profits
Valneva intends to file regulatory applications in 2026 to obtain approval for its VLA-15 vaccine candidate against Lyme disease from the competent regulatory authorities in Europe and the United States. This is subject to the successful completion of the two phase III studies. According to Invest Securities, the results of these studies are expected at the end of 2025.
These announcements come as Valneva published its half-year results in mid-August, with the group returning to the green in terms of profits for the first six months of 2024.
The group should, in the second half of the year, benefit from an acceleration in sales of its vaccine against chikungunya, already launched in the United States, while the first sales in Canada and Europe should occur in the fourth quarter.
Julien Marion – ©2024 BFM Bourse
Are you following this action?
Receive all the information about VALNEVA in real time:
